Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 3% at the end of the session. The analysis results of the Chinese phase III clinical study on titacipr treatment GMG were announced at the AANEM annual meeting

The Zhitong Finance App learned that Rongchang Biotech (09995) rose more than 3% at the end of the session. As of press release, it had risen 3.01% to HK$77.05, with a turnover of HK$219 million.

According to the news, according to Rongchang Biotech's official WeChat account, on September 29, the latest post-mortem analysis results of Rongchang Biotech's Taitacip in the treatment of systemic myasthenia gravis (gMG) in China were publicly presented in the form of an oral report at the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) scientific conference during the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting.

Recently, Vor Bio announced that the global phase III clinical study (UPSTREAM MG) for the treatment of gmg with taitacip has completed patient enrollment. The top-line results for the 24-week main endpoints of the study are expected to be announced in the first half of 2027. Meanwhile, Vor Bio plans to launch its global phase III registered clinical study (Upstream OMg) for the treatment of ocular myasthenia gravis (OMg). The first patient enrollment is expected to be completed in the first half of 2027. Domestically, the indications for gMG treatment with titacipr were approved and marketed in May 2025. The phase III clinical study for OMG has completed patient enrollment, and the data is expected to be read out in the first half of 2027.